Hangzhou Qihan Biotech received FDA IND clearance for QT-019C, a universal allogeneic CAR T-cell therapy designed for autoimmune diseases. The therapy is engineered to stably express two CARs targeting CD19 and BCMA and is built from healthy-donor leukapheresis products to enable an off-the-shelf approach. The clearance sets the stage for clinical evaluation in the US, where autoimmune CAR T remains a heavily watched space given safety constraints and the need for scalable manufacturing. QT-019C’s dual-target construct reflects an emphasis on broadened antigen coverage and may also inform how future allogeneic designs address durability and relapse risk as developers move beyond early preclinical and single-target formats.